Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study - PubMed
3 hours ago
- #multiple myeloma
- #MRD-negativity
- #quadruplet therapy
- Quadruplet therapy (Isa-VRd) followed by Isa-Rd showed significant PFS benefit in transplant-ineligible NDMM patients in the IMROZ study.
- Higher rates of MRD-negativity and MRD-negative CR were achieved with Isa-VRd/Isa-Rd compared to VRd/Rd, up to 60 months of follow-up.
- Benefit was observed across key subgroups, including older (>70 years) and frail patients.
- Deeper responses correlated with improved outcomes, notably prolonged time-to-progression (TTP) for Isa-VRd/Rd.
- Monitoring MRD status at multiple timepoints may aid in treatment decisions and discontinuation.
- Isa-VRd quadruplet regimen is supported as a standard-of-care for front-line treatment of transplant-ineligible NDMM patients.